CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ernexa Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ernexa Therapeutics Inc
1035 Cambridge Street, Suite 18A
Phone: (212) 582-1199p:212 582-1199 CAMBRIDGE, MA  02141  United States Ticker: ERNAERNA
Business Summary
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
4833 Television broadcasting stations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board JamesBristol 77 12/19/2023 10/30/2023
President, Chief Executive Officer, Director SanjeevLuther 62 1/1/2024 1/1/2024
Senior Vice President - Finance SandraGurrola 56 5/4/2023 9/8/2014
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Novellus Therapeutics Limited 7-8 Wilton Terrace Dublin 2 United Kingdom

Business Names
Business Name
Brooklyn ImmunoTherapeutics, Inc.
BTX
ERNA
5 additional Business Names available in full report.

General Information
Number of Employees: 6 (As of 3/10/2025)
Outstanding Shares: 52,244,929 (As of 3/10/2025)
Shareholders: 146
Stock Exchange: NASD
Federal Tax Id: 311103425
Fax Number: (302) 655-5049
Email Address: investor@ntn.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025